醫(yī)療特長(zhǎng)：
1987年畢業(yè)于中山醫(yī)科大學(xué),，于中山大學(xué)腫瘤防治中心從事腫瘤放療領(lǐng)域近三十年，是資深臨床放射治療學(xué)專家,。
擅長(zhǎng)頭頸部腫瘤（包括鼻咽癌,、喉癌、下咽癌等）以及前列腺癌等多種惡性腫瘤的診斷,、化學(xué)治療和放射治療為主的腫瘤綜合治療,。
研究方向：
頭頸部腫瘤（包括鼻咽癌、喉癌,、下咽癌等）以及前列腺癌等多種惡性腫瘤的放化綜合治療,。
主要教育和工作經(jīng)歷：
教育經(jīng)歷:
1. 1981/09 - 1987/07,，中山醫(yī)科大學(xué)（臨床醫(yī)學(xué)），學(xué)士
2. 1994/09 - 1997/12,，中山醫(yī)科大學(xué)（腫瘤學(xué)）,，碩士
工作經(jīng)歷:
1. 1987/07-1994/11，中山大學(xué)腫瘤防治中心/放療科,，住院醫(yī)師
2. 1994/11-2002/1,，中山大學(xué)腫瘤防治中心/放療科，主治醫(yī)師
3. 2002/01-2014/12,，中山大學(xué)腫瘤防治中心/放療科,，副主任醫(yī)師，兼任放療門(mén)診區(qū)長(zhǎng)
4. 2014/12-2017/05,，中山大學(xué)腫瘤防治中心/放療科,，主任醫(yī)師，兼任放療門(mén)診區(qū)長(zhǎng)
5.2017/05-至今,，中山大學(xué)附屬第一醫(yī)院/放射治療科,，主任醫(yī)師、科室主任
社會(huì)兼職：
廣東省醫(yī)師協(xié)會(huì)放射治療醫(yī)師分會(huì)常委
論著（SCI,，第一作者/通信作者）：
(1) Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma an analysis of a phase III randomized trial.Scientific Reports.(IF=5.578)
(2) Development and external validation of nomograms for predicting survival in nasopharyngeal carcinoma patients after definitive radiotherapy. Scientific Reports.(IF=5.578)
(3) Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. (IF=4.889)
(4) Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. International Journal of Radiation Oncology Biology Physics. (IF=4.258)
(5) Overexpression of chromosome 14 open reading frame 166 correlates with disease progression and poorer prognosis in human NPC. Tumor Biology. (IF=3.611)
(6) Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy? BMC Cancer. (IF=3.362 )
(7) Prognostic significance of maximum primary tumor diameter in nasopharyngeal carcinoma. BMC Cancer. (IF=3.362 )
(8) Primary tumor regression speed after radiotherapy and its prognostic significance in nasopharyngeal carcinoma: a retrospective study. BMC Cancer. (IF=3.362 )
(9) Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy. Radiation Oncology. (IF= 2.546)
(10) Spreading patterns, prognostic factors and treatment outcomes of nasopharyngeal papillary adenocarcinoma and salivary gland-type carcinomas. Clinical Otolaryngology. (IF=2.113 )
